News

Clinical stage biotech MoonLake Immunotherapeutics AG (NASDAQ: MLTX) shares spiked 70% on positive phase two clinical trial results. The company specializes in nanobodies, fragments of antibodies

Like most stocks during the dot-com bubble, GSK PLC (NYSE: GSK) partied like it was 1999. In the two decades since, missteps and competitive pressures slashed roughly 50% from the U.K. pharmaceuti

Developmental biomedical device company PetVivo Holdings Inc. (OTCMKTS: PETV) makes pet medical devices and therapeutics. What kind of medical devices would pets need? Pacemakers? Artificial hearts

On May 15, Sarepta Therapeutics Inc. (NASDAQ: SRPT) learned that its treatment for Duchenne muscular dystrophy (DMD) was recommended for approval by the Food and Drug Administration (FDA)

ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles that target and selectively deliver

Investors rarely get to consider a blue-chip company like T-Mobile US (NASDAQ: TMUS) amid a decline of more than 17% during the past two months. As the underlying stock carries a beta of only

Dogs and cats were among the biggest beneficiaries of the pandemic thanks to more attention from housebound pet owners. Pet adoption trends also skyrocketed. 

As Fido and Fluffy were spoiled more

Don’t be fooled by the fact that Novartis AG (NYSE:NVS) is trading near an all-time high. The Swiss pharmaceutical giant is still a good value.

That value proposition took a huge step forward on

The iShares Biotechnology ETF (NASDAQ: IBB) has recently shown signs of potential consolidation leading to a breakout. Such price action and development should prompt investors to notice possible

Tax software may not be the most glamorous business; as of today, no company in that industry has launched a virtual reality headset. However, if you’re scouting for a company with solid

If you think Advance Auto Parts's (NYSE: AAP) 10X valuation and 5% yield are attractive, don’t be fooled because the dividend just got cut, and the stock is heading lower, possibly much lower. The

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Administration (FDA). The company submitted, and

Pfizer Inc. (NYSE: PFE) released the results of a peer review study that sent shares up more than 5%. The study evaluated the company’s GLP-1 receptor agonist, danuglipron. The compound aimed to

Mid-cap chip-gear maker Axcelis Technologies Inc. (NASDAQ: ACLS) has been on a rocket ride, posting the following returns:

• 1 week: 9.68%

• 1 month: 13.66%

• 3 months: 14.26%

The insider buying activity is as interesting as usual, with some insiders selling and some buying. Among the more exciting details is that Warren Buffet started buying Occidental Petroleum (NYSE:

Pfizer Inc. (NYSE: PFE) continued its downward trajectory on May 17, following news that the Federal Trade Commission is seeking to block Amgen Inc.’s (NASDAQ: AMGN) planned acquisition of Horizon

Zoetis (NYSE: ZTS) shareholders may have a new reference point to be excited about, even after witnessing some favorable developments through the company's first quarter 2023 announcements. Even

Shares of Eagle Materials (NYSE: EXP) are rallying in the pre-market hours of Thursday morning as the company releases its quarterly earnings results, which delivered an exceptional quarter

Big pharmaceutical stocks, including Novartis AG (NYSE: NVS), Eli Lilly & Co. (NYSE: LLY), Merck & Co. (NYSE: MRK), and Novo Nordisk A/S (NYSE: NVO) have been outperforming the broader market

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), maker of Cystic fibrosis drugs, rallied to a record high on May 2 after a better-than-expected first-quarter earnings report. 

Net income of $3.05 a